What's Happening?
An international research team, led by The Institute of Cancer Research, London, and RCSI University of Medicine and Health Sciences, has identified potential new treatment targets for Microsatellite stable (MSS) colorectal cancer, the most common type
of bowel cancer. This form of cancer accounts for 80-85% of the 48,213 new bowel cancer cases diagnosed annually in the UK and has historically been challenging to treat with limited response to existing therapies. The study, published in the journal Cancer Cell, utilized an artificial intelligence (AI) approach called iPhenMap to analyze genetic, metabolic protein, and clinical data from 2,000 patient tumor samples. This AI tool created a biological map of the tumors, revealing previously unrecognized connections between tumor biology and therapeutic dependency. The researchers discovered vulnerabilities in these tumors and identified drug combinations, including existing approved drugs for other cancer types, that could effectively target them. For instance, the targeted drug trametinib, already approved for melanoma, lung, and thyroid cancers, significantly reduced tumor growth and extended survival in laboratory models when combined with other drugs.
Why It's Important?
This research offers a significant advancement in the treatment of MSS colorectal cancer, a type that has long presented a challenge due to its resistance to many newer therapies. By identifying new vulnerabilities and effective drug combinations, the study provides a clear roadmap for repurposing existing drugs and developing new, more personalized treatments. The use of AI and machine learning in this research is particularly important as it demonstrates how complex data integration can uncover insights missed by traditional methods, potentially accelerating the development of new oncology treatments. The findings could lead to more effective options for thousands of patients who currently have limited choices, improving their chances of living longer and healthier lives. The methodology also sets a precedent for applying AI to identify effective drugs for other tumor types, indicating a broader impact on cancer research and treatment strategies.
What's Next?
The immediate next step for this research is to accelerate the path to clinical testing of the identified new treatment strategies for bowel cancer. This will involve evaluating how these approaches can be safely advanced towards clinical evaluation and identifying the biological features that predict patient response. Professor Annette Byrne, Head of the RCSI Precision Cancer Medicine Group, emphasized the need to determine how these preclinical findings can be translated into clinical practice, particularly for patients with MSS RAS-mutant metastatic colorectal cancer who urgently need better treatment options. The researchers also believe their AI approach, iPhenMap, could be applied to identify more effective drugs for other tumor types, suggesting future research will likely explore this broader application. The collaboration with European partners and the funding from the European Union’s Horizon 2020 Research and Innovation Programme highlight a continued international effort in this field.
Beyond the Headlines
The study's reliance on artificial intelligence to integrate and analyze vast, diverse datasets represents a paradigm shift in cancer research. This AI-driven approach, which created a biological map of tumors, moves beyond traditional methods that often analyze data in isolation. This not only enhances the understanding of tumor behavior but also identifies therapeutic dependencies that were previously overlooked. The ethical implications of AI in medicine, particularly in drug discovery and personalized treatment, are profound, promising more precise and potentially less toxic therapies. Furthermore, the emphasis on repurposing existing drugs could significantly reduce the time and cost associated with bringing new treatments to market, making advanced therapies more accessible. This research underscores a growing trend towards international collaboration and interdisciplinary approaches, combining genomics, metabolomics, proteomics, and AI to tackle complex diseases like cancer, ultimately reshaping the future of oncology.
